Massachusetts Financial Services Co. MA Sells 20,617 Shares of Stryker Corporation $SYK

Massachusetts Financial Services Co. MA lowered its position in shares of Stryker Corporation (NYSE:SYK) by 9.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 195,835 shares of the medical technology company’s stock after selling 20,617 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Stryker were worth $67,841,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Sankala Group LLC bought a new position in Stryker in the 4th quarter valued at $26,000. Godfrey Financial Associates Inc. bought a new position in shares of Stryker in the fourth quarter worth $26,000. United Financial Planning Group LLC bought a new position in shares of Stryker in the third quarter worth $27,000. Atlas Capital Advisors Inc. purchased a new stake in shares of Stryker in the fourth quarter worth $27,000. Finally, DJE Kapital AG bought a new stake in Stryker during the fourth quarter valued at $28,000. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In other news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 4.60% of the stock is owned by company insiders.

Stryker Trading Down 0.7%

Shares of SYK stock opened at $338.80 on Friday. The business has a 50-day moving average price of $324.61 and a two-hundred day moving average price of $333.57. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The firm has a market cap of $129.95 billion, a P/E ratio of 35.11, a price-to-earnings-growth ratio of 2.17 and a beta of 0.76.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company’s revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the company earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts anticipate that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker’s dividend payout ratio is currently 36.48%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on SYK. Needham & Company LLC dropped their price target on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Barclays decreased their price objective on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research report on Monday, May 4th. UBS Group started coverage on shares of Stryker in a research note on Tuesday, July 28th. They issued a “buy” rating and a $400.00 target price on the stock. BMO Capital Markets assumed coverage on shares of Stryker in a research report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 target price for the company. Finally, JPMorgan Chase & Co. cut their price target on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.